ResearcherUniversity of MichiganActive in the last 2 years
Lifeng Yang
Matched on ORCID iD 0000-0001-5175-7589; OpenAlex author ID A5025588089. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 47
2017: 2 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 6
- Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/s41586-026-11134-x↗
- Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. Co-author DOI 10.1016/j.medj.2021.12.008↗
- Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer. Co-author DOI 10.7150/ijbs.60473↗
- Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. Co-author DOI 10.7554/elife.50663↗
- Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/nature21052↗
- Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ncomms14437↗
Closest collaborators
The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Deepak Nagrath · 4 shared papers, 2017–2026 · strength 0.38
- Paper Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. DOI 10.1038/s41586-026-11134-x↗
- Paper Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. DOI 10.7554/elife.50663↗
- Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
- Anirban Maitra · 3 shared papers, 2017–2026 · strength 0.33
- Paper Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. DOI 10.1038/s41586-026-11134-x↗
- Paper Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. DOI 10.7554/elife.50663↗
- Paper Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. DOI 10.1038/nature21052↗
- Huamin Wang · 3 shared papers, 2017–2026 · strength 0.32
- Paper Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. DOI 10.1038/s41586-026-11134-x↗
- Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
- Paper Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. DOI 10.1038/nature21052↗
- Haoqiang Ying · 3 shared papers, 2017–2026 · strength 0.32
- Paper Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. DOI 10.1038/s41586-026-11134-x↗
- Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
- Paper Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. DOI 10.1038/nature21052↗
- Ronald Anthony Depinho · 3 shared papers, 2017–2026 · strength 0.32
- Paper Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. DOI 10.1038/s41586-026-11134-x↗
- Paper Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal aden… DOI 10.1038/ncomms14437↗
- Paper Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. DOI 10.1038/nature21052↗
- Andrea Viale · 2 shared papers, 2017–2026 · strength 0.26
- Di Zhao · 2 shared papers, 2017–2026 · strength 0.26
- Ya’an Kang · 2 shared papers, 2017–2026 · strength 0.26
- Giannicola Genovese · 2 shared papers, 2017–2026 · strength 0.26
- Jason B. Fleming · 2 shared papers, 2017–2026 · strength 0.26
- Prasenjit Dey · 2 shared papers, 2017–2026 · strength 0.26
- Giulio Francesco Draetta · 2 shared papers, 2017–2026 · strength 0.26
- Tony Gutschner · 2 shared papers, 2017–2026 · strength 0.26
- Joshua D. Rabinowitz · 2 shared papers, 2021–2022 · strength 0.24
- Wenyun Lu · 1 shared paper, 2022 · strength 0.12
- Michel Nofal · 1 shared paper, 2022 · strength 0.12
- Gaoyang Liang · 1 shared paper, 2022 · strength 0.12
- Matthew Joseph McBride · 1 shared paper, 2022 · strength 0.12
- Serina Ng · 1 shared paper, 2022 · strength 0.12
- Haiyong Han · 1 shared paper, 2022 · strength 0.12
- Ronald M. Evans · 1 shared paper, 2022 · strength 0.12
- Daniel D. Von Hoff · 1 shared paper, 2022 · strength 0.12
- Thuy Xuan Phan · 1 shared paper, 2021 · strength 0.12
- Marcela d'Alincourt Salazar · 1 shared paper, 2021 · strength 0.12
- Laleh Golkar Melstrom · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.